Lithium Ion

Lithium Ion

SCHEMBL7281502

O=C([O-])CC=P(c1ccccc1)(c1ccccc1)c1ccccc1.[Li+]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.41
USP2 O75604 1/20 0.38
CFTR P13569 1/20 0.36
CA2 P00918 2/20 0.35
CA4 P22748 2/20 0.35
CA5A P35218 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
CES2 O00748 2/20 0.34
CES1 P23141 2/20 0.34
TSHR P16473 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27728842 0.82 HSP90AA1 (0.44) HSP90AA1USP2CFTRCA2CA4
SCHEMBL3115111 0.82 USP2 (0.47) HSP90AA1USP2CFTRCA2CA4
SCHEMBL7281507 0.80 USP2 (0.45) HSP90AA1USP2CFTRCA2CA4
Bromide SCHEMBL5222954 0.80 USP2 (0.45) HSP90AA1USP2CFTRCA2CA4
SCHEMBL7063121 0.78 HSP90AA1 (0.42) HSP90AA1USP2CFTRCA2CA4
SCHEMBL5222945 0.78 HSP90AA1 (0.42) HSP90AA1USP2CFTRCA2CA4
SCHEMBL10538450 0.77 MAPT (0.48) HSP90AA1HDAC3HDAC4HDAC1HDAC7
SCHEMBL27646839 0.77 HSP90AA1 (0.41) HSP90AA1USP2CFTRCA2CA4
Potassium Ion SCHEMBL5386445 0.75 HDAC3 (0.46) HSP90AA1CFTRHDAC3HDAC4HDAC1
SCHEMBL11072297 0.75 HDAC3 (0.50) HSP90AA1CFTRCA2CA4CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0550111-B1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them SANOFI SA (FR) 1999-04-14 EP disclosed
US-5856349-A 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof SANOFI (FR) 1999-01-05 US disclosed
US-5783589-A 2-saccharinylmethyl aryl and arloxy acetates useful as proteolytic enzyme inhibitors and compositions and method of use thereof SANOFI (FR) 1998-07-21 US disclosed
US-5652254-A TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS SANOFI, S.A. (FR) 1997-07-29 US disclosed
EP-0549073-B1 Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof SANOFI SA (FR) 1997-03-26 EP disclosed
US-5597841-A 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP, INC. (US) 1997-01-28 US disclosed
US-5563163-A TREATMENT OF DEGENERATIVE DISEASES STERLING WINTHROP, INC. (US) 1996-10-08 US disclosed
EP-0594257-B1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC (US) 1996-07-10 EP disclosed
US-5512589-A TREATING DEGENERATIVE DISEASES STERLING WINTHROP INC. (US) 1996-04-30 US disclosed
US-5489604-A TREATING DEGENERATIVE DISEASES STERLING WINTHROP, INC. (US) 1996-02-06 US disclosed
EP-0594257-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1994-04-27 EP disclosed
US-5306818-A Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis STERLING WINTHROP INC. (US) 1994-04-26 US disclosed
US-5296496-A Treating degenerative diseases STERLING WINTHROP INC. (US) 1994-03-22 US disclosed
US-5250696-A Treatment of degenerative diseases STERLING WINTHROP INC. (US) 1993-10-05 US disclosed
EP-0550112-A1 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed
EP-0550111-A1 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them STERLING WINTHROP INC. (US) 1993-07-07 EP disclosed
EP-0549073-A1 Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof STERLING WINTHROP INC. (US) 1993-06-30 EP disclosed
US-5187173-A Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders STERLING WINTHROP INC. (US) 1993-02-16 US disclosed
US-5128339-A Emphysema, rheumatoid arthritis, pancreatitis STERLING WINTHROP INC. (US) 1992-07-07 US disclosed
EP-0483928-A1 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use STERLING WINTHROP INC. (US) 1992-05-06 EP disclosed